News

Madrigal Pharma Bolstered By Equity Infusion, Buy Into 2024 (NASDAQ:MDGL)

8 Mins read

Madrigal Pharmaceuticals (NASDAQ:MDGL) is currently transitioning from the clinical trial stage to preparing market-ready solutions primarily aimed at addressing non-alcoholic steatohepatitis (NASH) and liver fibrosis. Their leading candidate, Resmetirom, is now in Phase III clinical trials and is anticipated to enter the market

Read the full article here

Related posts
News

Wall Street Breakfast Podcast: Markets March Higher

2 Mins read
Listen below or on the go on Apple Podcasts and Spotify Stock index futures rise ahead of busy earnings week, inflation data….
News

Mercer Stock Trades For A Price Because Its Financial Risk Is Real And Near (NASDAQ:MERC)

1 Mins read
This article was written by Follow Long-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics…
News

Pearson plc (PSO) Q3 2025 Sales Call Transcript

1 Mins read
Unknown Executive Good morning, everyone, and welcome to Pearson’s 2025 9-month Trading Update. [Operator Instructions]. And with that, I’ll hand over to…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *